<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02776605</url>
  </required_header>
  <id_info>
    <org_study_id>PONALFIL</org_study_id>
    <nct_id>NCT02776605</nct_id>
  </id_info>
  <brief_title>Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia</brief_title>
  <acronym>PONALFIL</acronym>
  <official_title>Concurrent Ponatinib With Chemotherapy for Young Adults With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PETHEMA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PETHEMA Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the response (complete hematologic response [CHR], complete cytogenetic response&#xD;
      [CCyR], major molecular response [MMR] and complete molecular response [CMR] of the&#xD;
      combination of ponatinib with standard chemotherapy (according to PETHEMA ALL Ph08 trial) in&#xD;
      young patients with Ph+ (BCR-ABL) ALL.&#xD;
&#xD;
      All patients are treated with:&#xD;
&#xD;
      Pre-phase (maximum 7 days, -7 to -1):&#xD;
&#xD;
      Prednisone 60 mg/m2/day IV over 7 days (-7 a -1) and triple intrathecal therapy (TIT)&#xD;
      (Methotrexate [MTX]: 12 mg, ARA-C: 30 mg, hydrocortisone: 20 mg). 2. Induction (day 1 to day&#xD;
      28 or up to hematological recovery) Vincristine (VCR): 1.5 mg/m2 (maximum 2 mg) IV days 1, 8,&#xD;
      15 and 22. Daunorubicin (DNR): 45 mg/m2 IV days 1, 8, 15 and 22. Prednisone (PDN): 60&#xD;
      mg/m2/day, IV or PO, days 1 to 27. Ponatinib 30 mg, PO from day 1 to consolidation. TIT, days&#xD;
      1 and 22. 3. Consolidation (day 1 to day 63) Mercaptopurine (MP): 50 mg/m2, PO days 1 to 7,&#xD;
      28 to 35 and 56 to 63. MTX: 1,5 g/m2, IV (24 h continuous infusion) days 1, 28 and 56. VP-16:&#xD;
      100 mg/m2/12 h, IV, days 14 and 42. ARA-C: 1000 mg/m2/12 h, IV, days 14-15 and 42-43. TIT&#xD;
      (MTX: 12 mg, ARA-C: 30 mg, hydrocortisone: 20 mg), , days 1, 28 and 56. Ponatinib 30 mg/d PO,&#xD;
      from day 1 to 15 days before HSCT. 4. HSCT (performed ideally within 1 month from the end of&#xD;
      consolidation). AlloHSCT preferred over autoHSCT (autoHSCT only indicated if alloHSCT not&#xD;
      feasible). Myeloablative conditioning with cyclophosphamide and total body irradiation (TBI)&#xD;
      whenever possible. 5. Post HSCT therapy After alloHSCT. Frequent monitoring of MRD (every&#xD;
      month). I After autoHSCT: Frequent monitoring of MRD (every month).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives Primary&#xD;
&#xD;
        1. To evaluate the response (complete hematologic response [CHR], complete cytogenetic&#xD;
           response [CCyR], major molecular response [MMR] and complete molecular response [CMR] of&#xD;
           the combination of ponatinib with standard chemotherapy (according to PETHEMA ALL Ph08&#xD;
           trial) in young patients with Ph+ (BCR-ABL) ALL.&#xD;
&#xD;
        2. To evaluate the event free survival (EFS) of the combination of ponatinib with standard&#xD;
           chemotherapy (according to PETHEMA ALL Ph08 trial) in young patients with Ph+ (BCR-ABL)&#xD;
           ALL. Secondary&#xD;
&#xD;
             -  To evaluate the rate of patients receiving an allogeneic hematopoietic stem cell&#xD;
                transplant (alloHSCT) in first CR&#xD;
&#xD;
             -  To evaluate the frequency of MMR and CMR at the time of alloHSCT&#xD;
&#xD;
             -  To evaluate the transplant-related mortality (TRM)&#xD;
&#xD;
             -  To evaluate the CR duration and overall survival (OS) of the combination of&#xD;
                ponatinib with standard chemotherapy (according to PETHEMA ALL Ph08 trial) in young&#xD;
                patients with Ph+ (BCR-ABL) ALL.&#xD;
&#xD;
             -  To evaluate the outcome measures (CR duration, OS and EFS) in context of those&#xD;
                observed in the PETHEMA ALL Ph08 trial.&#xD;
&#xD;
             -  To observe the type and number of BCR-ABL kinase domain mutations developing during&#xD;
                and after the study.&#xD;
&#xD;
             -  To evaluate side effects, adverse events (AE) and serious AE (SAE).&#xD;
&#xD;
      Interventions:&#xD;
&#xD;
        1. Pre-phase (maximum 7 days, -7 to -1):&#xD;
&#xD;
           Prednisone 60 mg/m2/day IV over 7 days (-7 a -1) and triple intrathecal therapy (TIT)&#xD;
           (Methotrexate [MTX]: 12 mg, ARA-C: 30 mg, hydrocortisone: 20 mg).&#xD;
&#xD;
        2. Induction (day 1 to day 28 or up to hematological recovery) Vincristine (VCR): 1.5 mg/m2&#xD;
           (maximum 2 mg) IV days 1, 8, 15 and 22. Daunorubicin (DNR): 45 mg/m2 IV days 1, 8, 15&#xD;
           and 22. Prednisone (PDN): 60 mg/m2/day, IV or PO, days 1 to 27. Ponatinib 30 mg, PO from&#xD;
           day 1 to consolidation. TIT, days 1 and 22.&#xD;
&#xD;
        3. Consolidation (day 1 to day 63) Mercaptopurine (MP): 50 mg/m2, PO days 1 to 7, 28 to 35&#xD;
           and 56 to 63. MTX: 1,5 g/m2, IV (24 h continuous infusion) days 1, 28 and 56. VP-16: 100&#xD;
           mg/m2/12 h, IV, days 14 and 42. ARA-C: 1000 mg/m2/12 h, IV, days 14-15 and 42-43. TIT&#xD;
           (MTX: 12 mg, ARA-C: 30 mg, hydrocortisone: 20 mg), , days 1, 28 and 56. Ponatinib 30&#xD;
           mg/d PO, from day 1 to 15 days before HSCT.&#xD;
&#xD;
        4. HSCT (performed ideally within 1 month from the end of consolidation). AlloHSCT&#xD;
           preferred over autoHSCT (autoHSCT only indicated if alloHSCT not feasible).&#xD;
           Myeloablative conditioning with cyclophosphamide and total body irradiation (TBI)&#xD;
           whenever possible.&#xD;
&#xD;
        5. Post HSCT therapy After alloHSCT. Frequent monitoring of MRD (every month). If MRD&#xD;
           negative: no therapy. If MRD positive, Ponatinib 30 mg/d, po, until 2 yr. after HSCT.&#xD;
           The ponatinib dose will be reduced to 15 mg/d in the second year in patients with&#xD;
           sustained molecular response. After autoHSCT: Frequent monitoring of MRD (every month).&#xD;
           All patients will receive Ponatinib: 30 mg/d, PO, mercaptopurine, (40 mg/m2/d, PO) and&#xD;
           methotrexate (15 mg/m2/week, IM), during the first year after HSCT. The ponatinib dose&#xD;
           will be reduced to 15 mg/d in the second year in patients with sustained molecular&#xD;
           response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Actual">August 5, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the response (complete hematologic response [CHR], complete cytogenetic response [CCyR], major molecular response [MMR] and complete molecular response [CMR] of the combination of ponatinib with standard chemotherapy (according to PETHEMA ALL Ph08 trial) in young patients with Ph+ (BCR-ABL) ALL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event free survival</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the event free survival (EFS) of the combination of ponatinib with standard chemotherapy (according to PETHEMA ALL Ph08 trial) in young patients with Ph+ (BCR-ABL) ALL</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>ALL</condition>
  <arm_group>
    <arm_group_label>Ponatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-phase (maximum 7 days, -7 to -1) with Prednisone and triple intrathecal therapy (TIT)&#xD;
Induction (day 1 to day 28 or up to hematological recovery) Vincristine (VCR): 1.5 mg/m2 IV days 1, 8, 15 and 22. Daunorubicin (DNR): 45 mg/m2 IV days 1, 8, 15 and 22. Prednisone (PDN): 60 mg/m2/day, IV or PO, days 1 to 27. Ponatinib 30 mg, PO from day 1 to consolidation. TIT, days 1 and 22.&#xD;
Consolidation Mercaptopurine (MP): 50 mg/m2, PO days 1 to 7, 28 to 35 and 56 to 63. MTX: 1,5 g/m2, IV days 1, 28 and 56. VP-16: 100 mg/m2/12 h, IV, days 14 and 42. ARA-C: 1000 mg/m2/12 h, IV, days 14-15 and 42-43. TIT days 1, 28 and 56. Ponatinib 30 mg/d PO, from day 1 to day 7 before HSCT&quot;.&#xD;
HSCT (performed ideally within 1 month from the end of consolidation).&#xD;
Post HSCT therapy (MRD monitoring)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone 60 mg/m2/day IV over 7 days (-7 a -1) and triple intrathecal therapy (TIT)</description>
    <arm_group_label>Ponatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Vincristine (VCR): 1.5 mg/m2 (maximum 2 mg) IV days 1, 8, 15 and 22.</description>
    <arm_group_label>Ponatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <description>Daunorubicin (DNR): 45 mg/m2 IV days 1, 8, 15 and 22.</description>
    <arm_group_label>Ponatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone (PDN): 60 mg/m2/day, IV or PO, days 1 to 27.</description>
    <arm_group_label>Ponatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ponatinib</intervention_name>
    <description>Ponatinib 30 mg, PO from day 1 to consolidation</description>
    <arm_group_label>Ponatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine</intervention_name>
    <description>Mercaptopurine (MP): 50 mg/m2, PO days 1 to 7, 28 to 35 and 56 to 63.</description>
    <arm_group_label>Ponatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>MTX: 1,5 g/m2, IV (24 h continuous infusion) days 1, 28 and 56</description>
    <arm_group_label>Ponatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VP-16</intervention_name>
    <description>VP-16: 100 mg/m2/12 h, IV, days 14 and 42</description>
    <arm_group_label>Ponatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARA-C:</intervention_name>
    <description>ARA-C: 1000 mg/m2/12 h, IV, days 14-15 and 42-43.</description>
    <arm_group_label>Ponatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TIT</intervention_name>
    <description>TIT (MTX: 12 mg, ARA-C: 30 mg, hydrocortisone: 20 mg), , days 1, 28 and 56.</description>
    <arm_group_label>Ponatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ponatinib</intervention_name>
    <description>Ponatinib 30 mg/d PO, from day 1 to 15 days before HSCT.</description>
    <arm_group_label>Ponatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous transplantation</intervention_name>
    <description>Myeloablative conditioning with cyclophosphamide and total body irradiation (TBI) whenever possible and autologous transplantation</description>
    <arm_group_label>Ponatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allo transplantation</intervention_name>
    <description>Myeloablative conditioning with cyclophosphamide and total body irradiation (TBI) whenever possible and allo transplantation</description>
    <arm_group_label>Ponatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-55 yr.&#xD;
&#xD;
          -  De novo Ph+ (BCR-ABL)ALL&#xD;
&#xD;
          -  ECOG score ≤2 unless due to ALL&#xD;
&#xD;
          -  Absence of significant liver disease, as defined by the following criteria: total&#xD;
             serum bilirubin ≤1.5 x upper limit of normal (ULN), unless due to Gilbert's syndrome,&#xD;
             alanine aminotransferase (ALT) ≤2.5 × ULN or ≤5 x ULN if leukemic involvement of the&#xD;
             liver is present, and aspartate aminotransferase (AST) ≤2.5 × ULN or ≤5 x ULN if&#xD;
             leukemic involvement of the liver is present.&#xD;
&#xD;
          -  Adequate pancreatic function as defined by serum lipase and amylase ≤1.5 × ULN.&#xD;
&#xD;
          -  No history of dyslipidemia, hypertension, thrombotic events or cardiac disease.&#xD;
&#xD;
          -  For females of childbearing potential, a negative pregnancy test must be documented&#xD;
             prior to randomization. Female and male patients who are fertile must agree to use an&#xD;
             effective form of contraception with their sexual partners from randomization through&#xD;
             4 months after the end of treatment.&#xD;
&#xD;
          -  informed consent signed, according to national regulation&#xD;
&#xD;
          -  Patients aged between 56 and 60 years may be selected who could be included in the&#xD;
             study with the authorization of the Coordinating Investigator with the consolidation&#xD;
             treatment modified as follows:&#xD;
&#xD;
        Mercaptopurine (MP): 50 mg / m2, PO on days 1 to 7, 28 to 35 and 56 to 63 MTX: 0.75 g / m2,&#xD;
        IV (continuous infusion 24 h) on days 1, 28 and 56 ARA-C: 500 mg / m2 / 12 h, IV, days&#xD;
        14-15 and 42-43 TIT (MTX: 12 mg, ARA-C: 30 mg, hydrocortisone: 20 mg), days 1, 28 and 56&#xD;
        Ponatinib 30 mg / d PO, from day 1 to 7 days before HSCT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lymphoid blast crisis of CML,&#xD;
&#xD;
          -  WHO performance status ≤ 50% (Karnofsky) or ≥ 3 (ECOG).&#xD;
&#xD;
          -  Active HBV or HCV hepatitis, or AST/ALT ≥ 2.5 x ULN and bilirubin ≥ 1.5 x ULN.&#xD;
&#xD;
          -  History of acute pancreatitis within 1 year of study or history of chronic&#xD;
             pancreatitis.&#xD;
&#xD;
          -  History of alcohol abuse.&#xD;
&#xD;
          -  Ongoing or active infections.&#xD;
&#xD;
          -  Uncontrolled hypertriglyceridemia (triglycerides &gt;450 mg/dL).&#xD;
&#xD;
          -  Clinically significant, uncontrolled or active cardiovascular disease, specifically&#xD;
             including, but not restricted to: Any history of myocardial infarction, stroke, or&#xD;
             revascularization, Unstable angina or transient ischemic attack within 6 months prior&#xD;
             to enrollment Congestive heart failure within 6 months prior to enrollment, or left&#xD;
             ventricular ejection fraction (LVEF) less than lower limit of normal per local&#xD;
             institutional standards History of clinically significant (as determined by the&#xD;
             treating physician) atrial arrhythmia Any history of ventricular arrhythmia Any&#xD;
             history of venous thromboembolism including deep venous thrombosis or pulmonary&#xD;
             embolism.&#xD;
&#xD;
          -  Uncontrolled hypertension (diastolic blood pressure &gt;90 mm Hg; systolic &gt;140 mm Hg).&#xD;
             Patients with hypertension should be under treatment on study entry to effect blood&#xD;
             pressure control.&#xD;
&#xD;
          -  Taking medications that are known to be associated with torsades de pointes.&#xD;
&#xD;
          -  Taking any medications or herbal supplements that are known to be strong inhibitors of&#xD;
             CYP3A4 within at least 14 days before the first dose of ponatinib.&#xD;
&#xD;
          -  Creatinine levels &gt; 2.5mg/dl or glomerular filtration rate (GFR) &lt; 20 ml/min or&#xD;
             proteinuria &gt;3.5 g/day.&#xD;
&#xD;
          -  Gastrointestinal (GI) function impairment, or a GI disease that may significantly&#xD;
             alter the absorption of study drugs.&#xD;
&#xD;
          -  Patients who are currently receiving treatment with any of the medications with&#xD;
             potential to prolong QT interval (listed in Appendix 4) if the medications cannot be&#xD;
             either discontinued or switched to a different medication prior to starting study&#xD;
             drug.&#xD;
&#xD;
          -  Patients who have received any investigational drug ≤ 4 weeks.&#xD;
&#xD;
          -  Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or&#xD;
             who have not recovered from side effects of such therapy.&#xD;
&#xD;
          -  Patients who are pregnant or breast feeding and adults of reproductive potential not&#xD;
             employing an effective method of birth control (women of childbearing potential must&#xD;
             have a negative serum pregnancy test within 48 hrs. prior to administration of&#xD;
             Ponatinib). Postmenopausal women must be amenorrheic for at least 12 months to be&#xD;
             considered of non-childbearing potential. Male and female patients must agree to&#xD;
             employ an effective barrier method of birth control throughout the study and for up to&#xD;
             4 months following discontinuation of study drugs.&#xD;
&#xD;
          -  Patients with a history of another primary malignancy that is currently clinically&#xD;
             significant or currently requires active intervention.&#xD;
&#xD;
          -  Patients unwilling or unable to comply with the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C H Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 16, 2016</study_first_submitted>
  <study_first_submitted_qc>May 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2016</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Mercaptopurine</mesh_term>
    <mesh_term>Ponatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

